Table 2.
Incidence of LH rises (≥10 IU/L) and of LH rises with P rises (≥3.18 nmol/L) measured at stimulation day 5 or 6 prior to the start of ganirelix treatment and during ganirelix treatment
| Ganirelix start day | % (95% CI), n/N | P value* | ||
|---|---|---|---|---|
|
LH rises |
Early |
Day 5 |
2.3 (1.4-3.4) |
< 0.01 |
| 22/955 | ||||
| Day 6 |
6.6 (5.2-8.2) |
|||
| 74/1113 | ||||
| Late |
Day 5 |
1.2 (0.6-2.0) |
0.06 |
|
| 11/949 | ||||
| Day 6 |
2.3 (1.4-3.3) |
|||
| 25/1096 | ||||
| LH+P rises | Early |
Day 5 |
1.0 (0.5-1.9) |
0.11 |
| 10/955 | ||||
| Day 6 |
2.0 (1.2-2.9) |
|||
| 22/1113 | ||||
| Late | Day 5 |
0.5 (0.2-1.2) |
0.44 | |
| 5/949 | ||||
| Day 6 | 0.9 (0.4-1.6) |
|||
| 10/1096 | ||||
Early indicates on start day of ganirelix treatment; Late indicates during ganirelix treatment. CI confidence intervals, LH luteinizing hormone, P progesterone. *Day 5 versus day 6.